QVance Announces Partnership
NextCell Pharma AB* comments on its subsidiary QVance’s partnership with bioMérieux Sweden AB, which aims to strengthen quality control analytics for cell and gene therapy products in the Nordic region. The collaboration will enhance QVance’s capacity to provide microbiological testing for advanced therapies.
QVance will also open their doors to bioMerieux’s customers, providing access to advanced analytics technology and offering educational resources including webinars and training to companies in the advanced therapies sector.
“This partnership with bioMérieux will provide a strong launchpad for QVance, positioning both QVance and NextCell Pharma firmly on the cell therapy map,” said Mathias Svahn, CEO of NextCell Pharma. “By establishing ourselves as leaders in quality control, we’re setting a solid foundation for future growth in the rapidly evolving advanced therapy landscape,” said Lindsay Davies, CSO of NextCell Pharma and co-founder of QVance.
QVance and bioMérieux will officially launch their partnership at ATMP Sweden in Malmö on November 25, 2024, marking the beginning of joint efforts to establish QVance as a quality control leader for advanced therapies in the Nordics. This partnership underscores NextCell Pharma’s commitment to advancing patient access to life-changing therapies through quality and innovation.
Link to QVance’s news
Link to bioMérrieux’s news
* NextCell Pharma AB, "NextCell" or the "Company", Nasdaq First North Growth Market: NXTCL